- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01251640
Combination With Gemcitabine in Advanced Pancreatic Cancer (BAGPAC)
A Multi-center, Phase I/II Study of BAY86-9766 in Combination With Gemcitabine in Patients With Locally Advanced Inoperable or Metastatic Pancreatic Cancer
Open-label, uncontrolled, Phase I/II study to evaluate safety and efficacy of BAY86-9766 plus gemcitabine in locally advanced, unresectable or metastatic pancreatic cancer.
Phase I: Dose escalation study investigating 20, 30 and 50 mg BAY86-9766 plus gemcitabine (1000mg/m2); determination of maximum tolerated dose and recommended phase 2 dose.
Phase II: Determination of response (RECIST 1.1; primary endpoint). Secondary endpoints: response duration, disease control rate, time to progression, progression-free survival, overall survival, safety and tolerability.
Tumor assessments at Screening and than every 8 weeks.; Safety evaluations at Screening and weekly throughout the study; Safety follow-up visit 30 days after the last dose of study treatment; Survival follow up monthly for up to 8 month after LPFV.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 2
- Fas 1
Kontakter och platser
Studieorter
-
-
-
Bruxelles - Brussel, Belgien, 1070
-
Bruxelles - Brussel, Belgien, 1090
-
Edegem, Belgien, 2650
-
-
-
-
-
CLERMONT-FERRAND Cedex 1, Frankrike, 63003
-
-
-
-
Colorado
-
Aurora, Colorado, Förenta staterna, 80045
-
-
Massachusetts
-
Pittsfield, Massachusetts, Förenta staterna, 01201
-
-
-
-
Lombardia
-
Brescia, Lombardia, Italien, 25124
-
-
Marche
-
Ancona, Marche, Italien, 60126
-
-
-
-
-
Oslo, Norge
-
Oslo, Norge, 0310
-
-
-
-
-
Bialystok, Polen, 15-027
-
Gdansk, Polen, 80-952
-
Warszawa, Polen, 02-781
-
-
-
-
-
London, Storbritannien
-
London, Storbritannien, SE1 9RT
-
London, Storbritannien, WC1E 6BT
-
-
-
-
-
Brno, Tjeckien, 602 00
-
Olomouc, Tjeckien, 775 20
-
-
-
-
-
Berlin, Tyskland, 13353
-
-
Baden-Württemberg
-
Heilbronn, Baden-Württemberg, Tyskland, 74078
-
-
Bayern
-
München, Bayern, Tyskland, 81377
-
-
Hessen
-
Marburg, Hessen, Tyskland, 35033
-
-
Nordrhein-Westfalen
-
Bochum, Nordrhein-Westfalen, Tyskland, 44892
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Male or female patients ≥18 years of age
- Histological or cytologically confirmed locally advanced, inoperable or metastatic pancreatic adenocarcinoma not amenable to curative radiotherapy or surgery
- Patients must have at least one uni-dimensional measurable lesion by CT or MRI according to RECIST, Version 1.1
- Resolution of all acute toxic effects of any prior local treatment to Common Terminology Criteria for Adverse Events (CTCAE) Grade </= 1
- Eastern Cooperative Oncology Group performance status (ECOG PS) </= 2
- Patient has cardiac function, within normal range, as measured by an echocardiogram
Exclusion Criteria:
- Known history of, or symptomatic metastatic brain or meningeal tumors
- History of cardiac disease
- Active clinically serious infections
- Clinically significant (ie. symptomatic) peripheral vascular disease
- Pregnant or lactating women; women of childbearing potential not employing adequate contraception
- Use of strong inhibitors or inducers of CYP3A4
- Prior systemic therapy for metastatic or locally advanced, unresectable pancreatic cancer, or other malignancy
- Previous gemcitabine or 5-fluorouracil (5-FU) given concurrently as radiosensitizers to radiation therapy in adjuvant intention if given within 6 months from start of study treatment
- Thrombotic or embolic events such within 6 months prior to start of study treatment
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Arm 1
|
Phase I: 40 mg/day (20 mg twice daily), 60 mg/day (30 mg twice daily, 100 mg/day (50 mg bid) dependent on safety/tolerability Phase II: Recommended Phase II dose (RP2D) dependent on the results of the Phase I part of this study Route of administration: Oral, twice daily (bid) in combination with gemcitabine 1000 mg/m2 Intravenous infusion over 30 minutes weekly for seven out of eight weeks (Cycle 1); followed by 1000 mg/m2 Intravenous infusion over 30 minutes weekly for three out of four weeks (Cycle 2 and subsequent)
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
Number of Subjects With Dose Limiting Toxicities (DLT): Phase I
Tidsram: From randomization up to the first 8 weeks of therapy
|
From randomization up to the first 8 weeks of therapy
|
Tumor Response (Adjudicated Blinded Read Assessment): Phase II
Tidsram: From start of treatment until 134 weeks assessed every 8 weeks
|
From start of treatment until 134 weeks assessed every 8 weeks
|
Sekundära resultatmått
Resultatmått |
Tidsram |
---|---|
Tumor Response: Investigator Assessment: Phase I
Tidsram: From start of treatment until 134 weeks assessed every 8 weeks
|
From start of treatment until 134 weeks assessed every 8 weeks
|
Disease Control (DC): Phase I
Tidsram: From start of treatment until 134 weeks assessed every 8 weeks
|
From start of treatment until 134 weeks assessed every 8 weeks
|
Disease Control (DC): Phase II
Tidsram: From start of treatment until 134 weeks assessed every 8 weeks
|
From start of treatment until 134 weeks assessed every 8 weeks
|
Duration of Response (DOR): Phase I
Tidsram: From start of treatment until 134 weeks assessed every 8 weeks
|
From start of treatment until 134 weeks assessed every 8 weeks
|
Duration of Response: Phase II
Tidsram: From start of treatment until 134 weeks assessed every 8 weeks
|
From start of treatment until 134 weeks assessed every 8 weeks
|
Time to Progression (TTP): Phase I
Tidsram: From start of treatment until 134 weeks assessed every 8 weeks
|
From start of treatment until 134 weeks assessed every 8 weeks
|
Time to Progression (TTP): Phase II
Tidsram: From start of treatment until 134 weeks assessed every 8 weeks
|
From start of treatment until 134 weeks assessed every 8 weeks
|
Progression-Free Survival (PFS): Phase I
Tidsram: From start of treatment until 134 weeks assessed every 8 weeks
|
From start of treatment until 134 weeks assessed every 8 weeks
|
Progression-Free Survival (PFS): Phase II
Tidsram: From start of treatment until 134 weeks assessed every 8 weeks
|
From start of treatment until 134 weeks assessed every 8 weeks
|
Overall Survival (OS): Phase I
Tidsram: From start of treatment until 134 weeks assessed every 8 weeks
|
From start of treatment until 134 weeks assessed every 8 weeks
|
Overall Survival (OS): Phase II
Tidsram: From start of treatment until 134 weeks assessed every 8 weeks
|
From start of treatment until 134 weeks assessed every 8 weeks
|
Samarbetspartners och utredare
Sponsor
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Matsmältningssystemets sjukdomar
- Neoplasmer
- Neoplasmer efter plats
- Sjukdomar i det endokrina systemet
- Neoplasmer i matsmältningssystemet
- Neoplasmer i endokrina körtel
- Bukspottkörtelsjukdomar
- Pankreatiska neoplasmer
- Läkemedels fysiologiska effekter
- Molekylära mekanismer för farmakologisk verkan
- Anti-infektionsmedel
- Antivirala medel
- Enzyminhibitorer
- Antimetaboliter, antineoplastiska
- Antimetaboliter
- Antineoplastiska medel
- Immunsuppressiva medel
- Immunologiska faktorer
- Gemcitabin
Andra studie-ID-nummer
- 14905
- 2010-019588-12 (EudraCT-nummer)
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Pankreatiska neoplasmer
-
Tianjin Medical University Cancer Institute and...Har inte rekryterat ännuPDAC - Pancreatic Ductal Adenocarcinoma
-
Sun Yat-sen UniversityRekryteringPDAC - Pancreatic Ductal AdenocarcinomaKina
-
Azienda Ospedaliera Universitaria Integrata VeronaRekryteringPDAC - Pancreatic Ductal AdenocarcinomaItalien
-
Azienda Ospedaliera Universitaria Integrata VeronaRekryteringPDAC - Pancreatic Ductal AdenocarcinomaItalien
-
Cedars-Sinai Medical CenterRekryteringPDAC - Pancreatic Ductal AdenocarcinomaFörenta staterna
-
Radboud University Medical CenterDutch Cancer SocietyRekryteringPDAC - Pancreatic Ductal AdenocarcinomaNederländerna
-
Imperial College LondonThe Leeds Teaching Hospitals NHS Trust; Sheffield Teaching Hospitals NHS... och andra samarbetspartnersRekryteringBukspottskörtelcancer | PDAC - Pancreatic Ductal AdenocarcinomaStorbritannien
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)AvslutadMetastatisk malign neoplasm | Ooperbar malign neoplasm | Avancerad malign neoplasmFörenta staterna
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Aktiv, inte rekryterandeMalign neoplasm | Metastatisk malign neoplasm | Avancerad malign neoplasm | Återkommande malign neoplasm | Lokalt avancerad malign neoplasmFörenta staterna
-
Massachusetts General HospitalRekryteringMalign neoplasm | Benign neoplasmFörenta staterna
Kliniska prövningar på BAY86-9766+Gemcitabine
-
BayerAvslutadKarcinom, hepatocellulärtBelgien, Frankrike, Schweiz, Tyskland, Förenta staterna, Österrike, Nya Zeeland, Ungern, Korea, Republiken av, Italien, Hong Kong, Thailand, Spanien, Taiwan, Japan, Tjeckien, Storbritannien
-
BayerAvslutad
-
BayerAvslutadNeoplasmerFörenta staterna, Tyskland, Nederländerna
-
BayerAvslutad
-
BayerAvslutadKarcinom, hepatocellulärtBelgien, Kina, Hong Kong, Schweiz, Japan, Frankrike, Spanien, Tyskland, Förenta staterna, Österrike, Tjeckien, Storbritannien, Korea, Republiken av, Thailand, Nya Zeeland, Ungern, Israel, Italien, Taiwan, Singapore, Kalkon
-
BayerAvslutad
-
BayerAvslutadMagnetisk resonanstomografiKina, Korea, Republiken av, Japan
-
Life Molecular Imaging SAAvslutad